Thursday, February 14, 2019 12:09:52 PM
Good points, I believe after over 10 yrs of developing, running trial after trial, its like a dog chasing its tail. things just keep going around in a circle with more and more dilution.
When I first came across the HP I thought it had great potential but for everything it claims to treat there always seems to be more effective ways to treat them by the time any trials get done. For ex. HCV, I remember the trials in India and all the big hullabaloo but then came better pharmaceutical trwatments and nothing ever became of the approval.
This company just keeps chasing the popular trend of the day but then a pharma treatment is approved which is a much easier and more effective way of treatment.
I think the only possible chance tbey have is if they can find a use for it that supplements and makes more effective oncology treatments which can be brutal with less than a 20% cure rate. They have made some headway with CTE but there again by the time they find its niche, get it tbrough trials and approved there will be more effective and less cumbersome ways of detection.
GLTA still holding
When I first came across the HP I thought it had great potential but for everything it claims to treat there always seems to be more effective ways to treat them by the time any trials get done. For ex. HCV, I remember the trials in India and all the big hullabaloo but then came better pharmaceutical trwatments and nothing ever became of the approval.
This company just keeps chasing the popular trend of the day but then a pharma treatment is approved which is a much easier and more effective way of treatment.
I think the only possible chance tbey have is if they can find a use for it that supplements and makes more effective oncology treatments which can be brutal with less than a 20% cure rate. They have made some headway with CTE but there again by the time they find its niche, get it tbrough trials and approved there will be more effective and less cumbersome ways of detection.
GLTA still holding
Recent AEMD News
- Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness • PR Newswire (US) • 05/21/2026 12:01:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 03:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:27:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:27:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:27:18 PM
- Advancements in Novel Immunotherapeutics in The Oncology Battle • Newsfile • 03/24/2026 02:30:00 PM
- Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review • PR Newswire (US) • 03/24/2026 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 01:15:09 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities • PR Newswire (US) • 03/12/2026 12:01:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th • GlobeNewswire Inc. • 03/06/2026 01:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:15:32 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/18/2026 01:22:47 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2026 10:10:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 09:15:44 PM
- Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update • PR Newswire (US) • 02/12/2026 09:15:00 PM
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026 • PR Newswire (US) • 02/04/2026 01:01:00 PM
